by Manon FRACHON | 7 Sep Thu | English
Jeito Capital co-leads oversubscribed financing Corteria, a late preclinical stage company, is developing first-in-class therapies with promising novel approaches for unaddressed heart failure subpopulations, addressing high unmet medical needs Jeito Capital marks its...
by Manon FRACHON | 13 Apr Thu | English
Funds will support the Phase I/II clinical development of Alentis’ two first-in-class anti-Claudin-1 (CLDN1) antibodies for organ fibrosis and CLDN1 positive tumors, and CLDN1 platform development After its investment 2 years ago, Jeito Capital amplifies its...
by Manon FRACHON | 7 Mar Tue | English
Noema Pharma’s clinical-stage assets and diversified pipeline hold significant potential in developing effective therapeutic options for patients with debilitating central nervous system (CNS) disorders, addressing high unmet medical needs Jeito Capital’s...
by Manon FRACHON | 6 Dec Tue | English
The Series C extension round will accelerate clinical development, manufacturing scale-up and pre-commercialization activities of Pulmocide’s lead product candidate, opelconazole. Paris, France, December 6th 2022 – Jeito Capital (“Jeito”), the...
by Manon FRACHON | 22 Nov Tue | English
Jeito Capital co-leads oversubscribed EUR 50 million Series C financing with Brandon Capital CatalYm is developing a new class of anti-cancer immunotherapies, which have already demonstrated initial promising clinical results in advanced-stage solid tumor patients...
Recent Comments